221 related articles for article (PubMed ID: 34797453)
21. Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.
Boughan KM; Caimi PF
Curr Oncol Rep; 2019 May; 21(7):63. PubMed ID: 31119485
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
23. The role of obinutuzumab in the management of follicular lymphoma.
O'Nions J; Townsend W
Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
[TBL] [Abstract][Full Text] [Related]
24. The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany.
Hofmann S; Himmler S; Ostwald D; Dünzinger U; Launonen A; Thuresson PO
J Comp Eff Res; 2020 Oct; 9(14):1017-1026. PubMed ID: 33016109
[TBL] [Abstract][Full Text] [Related]
25. High-risk follicular lymphoma: Treatment options.
Kahl B
Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
[TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.
Lansigan F; Barak I; Pitcher B; Jung SH; Cheson BD; Czuczman M; Martin P; Hsi E; Schöder H; Smith S; Bartlett NL; Leonard JP; Blum KA
Cancer Med; 2019 Jan; 8(1):165-173. PubMed ID: 30575311
[TBL] [Abstract][Full Text] [Related]
28. Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma-Moving to a model where less can be more.
Martynchyk A; Hawkes EA
Br J Haematol; 2024 May; 204(5):1582-1584. PubMed ID: 38581289
[TBL] [Abstract][Full Text] [Related]
29. Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies.
Rodgers TD; Casulo C; Boissard F; Launonen A; Parreira J; Cartron G
Oncol Ther; 2021 Dec; 9(2):329-346. PubMed ID: 34319556
[TBL] [Abstract][Full Text] [Related]
30. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study.
Tilly H; Morschhauser F; Casasnovas O; Molina TJ; Feugier P; Gouill SL; Haioun C; Tournilhac O; Bouabdallah R; Gabarre J; Lamy T; Cabeçadas J; Becker S; Jardin F; Mounier N; Salles G;
Lancet Haematol; 2018 Sep; 5(9):e403-e410. PubMed ID: 30172345
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study.
Fernández-Miranda I; Pedrosa L; Llanos M; Franco FF; Gómez S; Martín-Acosta P; García-Arroyo FR; Gumá J; Horcajo B; Ballesteros AK; Gálvez L; Martínez N; Marín M; Sequero S; Navarro M; Yanguas-Casás N; Calvo V; Rueda-Domínguez A; Provencio M; Sánchez-Beato M
Clin Cancer Res; 2023 Jan; 29(1):209-220. PubMed ID: 36269794
[TBL] [Abstract][Full Text] [Related]
33. When to treat patients with relapsed follicular lymphoma.
Cheah CY; Seymour JF
Expert Rev Hematol; 2017 Mar; 10(3):187-191. PubMed ID: 28164722
[TBL] [Abstract][Full Text] [Related]
34. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group.
Jurinovic V; Metzner B; Pfreundschuh M; Schmitz N; Wandt H; Keller U; Dreger P; Dreyling M; Hiddemann W; Unterhalt M; Hoster E; Weigert O
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1172-1179. PubMed ID: 29605716
[TBL] [Abstract][Full Text] [Related]
35. Follicular lymphoma: evolving therapeutic strategies.
Kahl BS; Yang DT
Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide: A Review in Previously Treated Follicular Lymphoma.
Blair HA
Drugs; 2020 Sep; 80(13):1337-1344. PubMed ID: 32803669
[TBL] [Abstract][Full Text] [Related]
37. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Wang M; Fowler N; Wagner-Bartak N; Feng L; Romaguera J; Neelapu SS; Hagemeister F; Fanale M; Oki Y; Pro B; Shah J; Thomas S; Younes A; Hosing C; Zhang L; Newberry KJ; Desai M; Cheng N; Badillo M; Bejarano M; Chen Y; Young KH; Champlin R; Kwak L; Fayad L
Leukemia; 2013 Sep; 27(9):1902-9. PubMed ID: 23545991
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory Agents in Follicular Lymphoma.
Ysebaert L; Morschhauser F
Hematol Oncol Clin North Am; 2020 Aug; 34(4):715-726. PubMed ID: 32586576
[TBL] [Abstract][Full Text] [Related]
39. Novel Therapy Approaches to Follicular Lymphoma.
Northend M; Townsend W
Drugs; 2021 Mar; 81(4):453-469. PubMed ID: 33616890
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide in follicular lymphoma.
Flowers CR; Leonard JP; Fowler NH
Blood; 2020 Jun; 135(24):2133-2136. PubMed ID: 32236519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
